CA3027682A1 - Reagents, compositions and methods for improving viability and function of cells, tissues and organs - Google Patents

Reagents, compositions and methods for improving viability and function of cells, tissues and organs Download PDF

Info

Publication number
CA3027682A1
CA3027682A1 CA3027682A CA3027682A CA3027682A1 CA 3027682 A1 CA3027682 A1 CA 3027682A1 CA 3027682 A CA3027682 A CA 3027682A CA 3027682 A CA3027682 A CA 3027682A CA 3027682 A1 CA3027682 A1 CA 3027682A1
Authority
CA
Canada
Prior art keywords
group
carbon atoms
alkyl group
substituted
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3027682A
Other languages
English (en)
French (fr)
Inventor
Shant DER SARKISSIAN
Nicolas NOISEUX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targa Biomedical
Original Assignee
Val Chum SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Val Chum SC filed Critical Val Chum SC
Publication of CA3027682A1 publication Critical patent/CA3027682A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/128—Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3027682A 2016-06-15 2017-06-15 Reagents, compositions and methods for improving viability and function of cells, tissues and organs Pending CA3027682A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350258P 2016-06-15 2016-06-15
US62/350,258 2016-06-15
PCT/CA2017/000151 WO2017214709A1 (en) 2016-06-15 2017-06-15 Reagents, compositions and methods for improving viability and function of cells, tissues and organs

Publications (1)

Publication Number Publication Date
CA3027682A1 true CA3027682A1 (en) 2017-12-21

Family

ID=60663810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3027682A Pending CA3027682A1 (en) 2016-06-15 2017-06-15 Reagents, compositions and methods for improving viability and function of cells, tissues and organs

Country Status (9)

Country Link
US (2) US11446265B2 (https=)
EP (1) EP3471733B1 (https=)
JP (3) JP7009463B2 (https=)
CN (2) CN109803664A (https=)
AU (1) AU2017285486B2 (https=)
CA (1) CA3027682A1 (https=)
DK (1) DK3471733T3 (https=)
ES (1) ES2992544T3 (https=)
WO (1) WO2017214709A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055817A1 (en) * 2017-09-14 2019-03-21 The Regents Of The University Of California EX VIVO CONSERVATION AND EXPANSION OF STEM CELLS
JP7404246B2 (ja) * 2018-02-14 2023-12-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー フォン・ヴィレブランド因子のレベルを調節する化合物、及び血液疾患の治療におけるそれらの使用
EP3833662B1 (en) 2018-08-20 2024-01-17 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
US20220023345A1 (en) * 2020-07-22 2022-01-27 Caladrius Biosciences, Inc. Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection
CN112375802A (zh) * 2020-11-06 2021-02-19 中国科学院城市环境研究所 评价白藜芦醇干预肺上皮细胞多环芳烃毒性效应的试剂或试剂盒及其应用和检测
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
WO2022212878A1 (en) * 2021-04-01 2022-10-06 The Regents Of The University Of California Human pluripotent stem cell-derived secretome as a biologic for prevention and treatment of neurodegenerative and apoptotic diseases
CN118634317B (zh) * 2024-08-16 2024-10-22 四川大学 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1112181C (zh) 2000-05-26 2003-06-25 北京大学 雷公藤属植物提取物在制备预防和治疗神经系统疾病药上的应用
KR20080031474A (ko) 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20100204093A1 (en) 2006-07-27 2010-08-12 University Of Florida Research Foundation, Inc Use of heat shock activators for tissue regeneration
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008063513A2 (en) 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
WO2009067245A2 (en) 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
CN101288671B (zh) 2008-04-17 2010-12-01 首都医科大学 雷公藤单体化合物在提高腺相关病毒载体介导的基因表达效率及其对神经退行性疾病的辅助治疗中的用途
JP2012511048A (ja) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Ｈｓｆ−１の改変方法
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
CN101756956A (zh) 2009-03-25 2010-06-30 赵亚力 儿茶素在制备逆转录病毒整合酶抑制剂中的应用
CN103524592B (zh) * 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
CA3044998A1 (en) 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体

Also Published As

Publication number Publication date
US20230024103A1 (en) 2023-01-26
US20210169830A1 (en) 2021-06-10
US11446265B2 (en) 2022-09-20
JP2022062037A (ja) 2022-04-19
CN121313845A (zh) 2026-01-13
EP3471733A4 (en) 2020-02-05
WO2017214709A8 (en) 2018-12-13
AU2017285486A1 (en) 2019-02-07
EP3471733B1 (en) 2024-08-07
CN109803664A (zh) 2019-05-24
DK3471733T3 (da) 2024-10-14
ES2992544T3 (es) 2024-12-13
JP7009463B2 (ja) 2022-01-25
EP3471733A1 (en) 2019-04-24
JP2019523784A (ja) 2019-08-29
AU2017285486B2 (en) 2023-04-27
US12419849B2 (en) 2025-09-23
JP2024019483A (ja) 2024-02-09
WO2017214709A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
US12419849B2 (en) Reagents, compositions and methods for improving viability and function of cells, tissues and organs
Pan et al. Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats
JP6548714B2 (ja) 放射線照射または化学物質による傷害を治療するための方法
Wu et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acetaminophen-induced acute liver failure through activating ERK and IGF-1R/PI3K/AKT signaling pathway
Tian et al. Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation
Chou et al. Stem cells and kidney regeneration
Amer et al. Role of adipose tissue derived stem cells differentiated into insulin producing cells in the treatment of type I diabetes mellitus
Hou et al. C1q tumor necrosis factor-related protein-3 protects mesenchymal stem cells against hypoxia-and serum deprivation-induced apoptosis through the phosphoinositide 3-kinase/Akt pathway
Wu et al. Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and Akt/eNOS signaling pathways
US20230277599A1 (en) Methods of Preserving Mesenchymal Stem Cells
BR112013004700B1 (pt) uso de células precursoras de células-tronco mesenquimais (msc) cd271+
AU2007243221A1 (en) Methods for treating diabetes
Liu et al. Mesenchymal stem cell (MSC)-mediated survival of insulin producing pancreatic β-cells during cellular stress involves signalling via Akt and ERK1/2
Wabitsch et al. Human stem cells promote liver regeneration after partial hepatectomy in BALB/C nude mice
Zhang et al. Effects of bone marrow and hepatocyte transplantation on liver injury
WO2019067491A1 (en) COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION
Briquet et al. Neuropeptides to replace serum in cryopreservation of mesenchymal stromal cells?
Schoenfeld et al. The existence of myocardial repair: mechanistic insights and enhancements
Ellis et al. Adipose stem cell secretome markedly improves rodent heart and hiPSC-derived cardiomyocyte recovery from cardioplegic transport solution exposure
Aminzadeh et al. Reversal of cardiac and skeletal manifestations of Duchenne muscular dystrophy by cardiosphere-derived cells and their exosomes in mdx dystrophic mice and in human Duchenne cardiomyocytes
HK40008604A (zh) 用於改善细胞、组织和器官的活力和功能的试剂、组合物和方法
Wang et al. Administration of donor-derived nonexpanded adipose stromal vascular fraction attenuates ischemia-reperfusion injury in donation after cardiac death rat renal transplantation
KR101648915B1 (ko) 줄기세포의 응집방지 방법 및 그 조성물
WO2020069215A1 (en) Bone marrow derived neurokinin-1 receptor positive (nk1r+) precursor cells for therapeutic applications
Clancy Autologous cells for renal allograft repair

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220525

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20240903

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250124

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250605

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250605

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250612

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250612

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250613

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260105